Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Depreciation & Amortization (CF) (2016 - 2025)

Collegium Pharmaceutical has reported Depreciation & Amortization (CF) over the past 10 years, most recently at $923000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $923000.0 for Q4 2025, down 11.34% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (up 8.45% YoY), and the annual figure for FY2025 was $4.2 million, up 8.45%.
  • Depreciation & Amortization (CF) for Q4 2025 was $923000.0 at Collegium Pharmaceutical, down from $1.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for COLL hit a ceiling of $1.1 million in Q2 2025 and a floor of $424000.0 in Q4 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $865000.0 (2023), compared with a mean of $797700.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 129.74% in 2021 and later dropped 11.34% in 2025.
  • Collegium Pharmaceutical's Depreciation & Amortization (CF) stood at $424000.0 in 2021, then surged by 94.58% to $825000.0 in 2022, then grew by 15.03% to $949000.0 in 2023, then grew by 9.69% to $1.0 million in 2024, then dropped by 11.34% to $923000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $923000.0 (Q4 2025), $1.0 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.